基于代谢组学研究参苓白术散对腹泻型肠易激综合征的作用机制
Study on the Mechanism of Action of ShenlingBaizhu Powder on Diarrhea-Predominant Irritable Bowel Syndrome Based on Metabolomics
DOI: 10.12677/TCM.2023.1212541, PDF, HTML, XML, 下载: 297  浏览: 408  国家自然科学基金支持
作者: 王 娟*, 王秋香, 吴瑞珂, 赵 方:成都中医药大学临床医学院,四川 成都;冯培民#:成都中医药大学临床医学院,四川 成都;成都中医药大学附属医院,四川 成都
关键词: 参苓白术散腺苷临床观察脾虚湿盛证型能量代谢ShenlingBaizhu Powder Adenosine Clinical Observation Spleen Deficiency and Excessive Dampness Syndrome Energy Metabolism
摘要: 目的:探讨参苓白术散对脾虚湿盛证型腹泻型肠易激综合征(IBS-D)疗效机制及IBS-D潜在生物标志物。方法:入组28例健康人为对照组,28例脾虚湿盛证型IBS-D为治疗组,治疗组给予参苓白术散,连续2周;采集对照组,治疗前后两组的血浆,三者两两比较;评估治疗前后两组的BSFS、IBS-SSS积分、IBS-QOL量表、HAMD和HAMA变化以及筛选血浆中差异代谢物,分析差异代谢物相关性和显著富集差异代谢物。结果:治疗后IBS-SSS总分、BSFS、腹胀程度、腹痛频率、腹痛程度、IBS-QOL显著降低;对生活的影响度,排便满意度,HAMA,HAMD均低于治疗前;与对照组对比,治疗前有24种差异代谢物,治疗后有47种差异代谢物,通过韦恩图、差异代谢物相关性分析及KEGG富集分析,α-酮戊二酸、乙酰乙酸、柠檬酸、中康酸4种代谢物被认为是IBS-D的潜在生物标志物,此外乙酰乙酸、柠檬酸、中康酸为下调,并且三者间呈正相关。与治疗前比较时,观察到有19种差异代谢物;治疗后差异代谢物主要富集在去甲吗啡、腺苷、富马酸3个代谢物,其次治疗后的α-酮戊二酸、柠檬酸、中康酸均低于治疗前。结论:IBS-D的发病机制可能与能量代谢异常有关,参苓白术散则改善能量代谢以及调节腺苷、去甲吗啡、富马酸代谢到达防治脾虚湿盛证型IBS-D疗效。
Abstract: Objective: The purpose of this study was to investigate the treatment mechanism of ShenlingBaizhu Powder for diarrhea-predominant irritable bowel syndrome (IBS-D) with spleen deficiency and ex-cessive dampness syndrome, as well as potential IBS-D biomarkers. Method: The control group con-sisted of 28 healthy people, while the treatment group comprised 28 patients with spleen deficien-cy and excessive dampness syndrome (IBS-D). Two consecutive weeks of ShenlingBaizhu Powder were administered to the treatment group. Collect plasma from the control group as well as before and after treatment, and compare them to each other. The BSFS, IBS-SSS score, IBS-QOL scale, HAMD, and HAMA changes were examined before and after treatment, and differential metabolites in plasma were screened to examine the association between differential metabolites and the sig-nificant enrichment of differential metabolites. Result: The IBS-SSS total score, BSFS, degree of ab-dominal distension, frequency of abdominal pain, degree of abdominal pain, and IBS-QOL were sig-nificantly reduced following treatment. The impact on life, defecation satisfaction, HAMA, and HAMD were all reduced after therapy compared to before. Before therapy, there were 24 different metab-olites compared to the control group, whereas there were 47 different metabolites after treatment. Four metabolites—alpha-ketoglutaric acid, acetoacetate, citric acid, and mesaconic acid—were identified as possible biomarkers for IBS-D using a Venn diagram, differential metabolite correla-tion analysis, and KEGG enrichment analysis. Additionally, acetoacetate, citric acid, and mesaconic acid are down-regulated, and the three have a positive association. Compared to before treatment, 19 differential metabolites were identified; the differential metabolites after treatment were pri-marily enriched with three metabolites: Normorphine, adenosine, and fumaric acid. Second, the levels of alpha-ketoglutaric acid, citric acid, and mesaconic acid were lower after therapy than be-fore treatment. Conclusion: Abnormal energy metabolism may be connected to the pathophysiology of IBS-D. ShenlingBaizhu Powder promotes energy metabolism and modulates adenosine, normor-phine, and fumaric acid metabolism to prevent and treat IBS-D with spleen deficiency and excessive dampness syndrome.
文章引用:王娟, 王秋香, 吴瑞珂, 赵方, 冯培民. 基于代谢组学研究参苓白术散对腹泻型肠易激综合征的作用机制[J]. 中医学, 2023, 12(12): 3629-3644. https://doi.org/10.12677/TCM.2023.1212541

1. 引言

肝胃不和是中医常见证型,多指由于肝郁气滞,横逆犯胃,进而导致胃失和降。临床表现为胃脘、两胁胀痛,嗳气呃逆,吞酸嘈杂,食少纳差,情志抑郁,善太息,急躁易怒,舌红苔薄黄,脉弦或弦数。中医认为,肝与胃在生理功能与病理变化上关系密切,主要体现在气机升降、水谷运化、气血化生三个方面。肝主疏泄、主藏血,胃主受纳腐熟,同居中焦,是气机升降之枢纽,肝之疏泄调畅气机、升发阳气,启迪诸脏,肝气泄之于脾胃,助脾胃运化有力,气血生化才能源源不断。《素问·经脉别论》又云:“食气入胃,散精于肝……留于四脏。”

《灵枢·营气》曰:“谷入于胃,乃传于肺,流溢于中,布散于外。”饮食入胃,经胃腑受纳腐熟、脾脏运化,将产生并吸收的水谷精微物质转输于脏腑、筋脉等全身各处,以充养先天之精,滋养后天之形,故曰脾胃为后天之本,气血生化之源 [1] 。脾胃化生气血以濡养肝血,肝之阴血制生肝之阳气,以保肝之疏泄出现太过或不及,肝主升发,肝阴与肝阳协调,肝气冲和条达。胃土主降,胆亦随胃降,胆又为肝之余气,胃之受纳腐熟也依赖于胆汁。故肝胃和则气机顺、气血和。

2. HP感染与抑郁症

2.1. HP感染

HP是螺杆菌属的代表菌种,是一种革兰氏阴性菌,主要定植在胃上皮细胞和胃粘膜中。HP感染后胃粘膜的炎症性改变称为幽门螺杆菌相关性胃炎(HPAG),其特征为打嗝、恶心、食欲不振、反酸、非典型性腹痛、腹胀、腹部不适等。如果治疗不及时,可能发展为胃癌 [2] ,1994年世界卫生组织和国际癌症研究机构已经将HP划分为I类致癌物 [3] ,我国自然人群中HP感染率高达56.22%,即HP感染患者约有7亿人次,但其根除率却逐年下降 [4] 。HP感染是一种感染性疾病 [5] ,并且有家庭聚集现象 [6] ,不管有无症状和并发症,根除治疗对象可扩展至无症状者 [7] 。近年来发现HP感染还和心血管系统、血液系统、神经系统、肿瘤、精神疾病等多系统的疾病密切相关 [8] 。

2.2. 抑郁症

抑郁症是以显著而持久的心境低落为主要特征的一类心境障碍,是最常见的精神障碍之一,临床主要表现为长期情绪低落、思维迟缓、兴趣减退。预计到2030年将成为全球疾病负担的第一位 [9] ,且全球每年有近80万人因抑郁症自杀身亡 [10] ,抑郁症可导致自杀,目前已经成为世界第四大疾患 [11] 。国内外的研究表示躯体化症状是抑郁症患者的主要临床表现 [12] [13] ,多数患者首诊以胃肠道症状、躯体疼痛及睡眠障碍等症状为主诉,常见的躯体化症状就是胃肠道症状。

临床上存在着HP感染与抑郁症共病的情况,有大量的证据证明两者存在一定的联系。临床发现HP感染的抑郁症患者的汉密尔顿抑郁量表(HAMD)抑郁评分明显高于非HP感染的抑郁症患者,根除HP对抑郁症患者的病情好转有显著促进作用 [14] 。在抑郁症常见的躯体化症状里,胃肠道等消化系统的症状最为常见 [15] 。Koloski等人在研究中发现人群先出现了胃肠道症状,然后才是心理困扰的发展 [16] 。另一方面,有研究发现未感染HP的人暴露于应激状态后,更容易感染HP [17] 。在临床上,医生尝试在患有消化系统疾病的患者的治疗中使用选择性5-羟色胺再摄取抑制剂(SSRI)西酞普兰可以减少消化不良症状,显著减少焦虑和抑郁,并改善生活质量 [18] 。一些难治性功能性消化不良患者在抗HP的标准方案中加入抗抑郁药物如TCAs (三环类抗抑郁药)或SSRIs后反应良好 [19] 。

3. HP感染与抑郁症共病中医病因病机分析

3.1. HP感染的中医病因病机

中医古籍没有关于HP或幽门螺旋杆菌病名的记载,中医诊治注重整体观念和辨证论治,从HP感染患者的症状以及体征,多归属于中医“胃脘痛”、“痞满”、“嘈杂”、“呃逆”、“反酸”等范围。HP相关性胃病的病因病机主要为外邪侵袭、情志失调、痰湿内蕴、饮食不节、瘀血阻滞、脾胃虚弱等,病位在胃,与肝脾有关 [20] 。中医认为HP自外侵袭人体,是属于“邪气”的一种,目前大部分学者认为,HP为湿热之邪 [21] 。脾胃虚弱是HP感染致病之本 [22] ,《素问·评热论》曰:“正气存内,邪不可干,邪之所凑,其气必虚”,脾胃虚弱,气血生化无源,正气不足不足以抵挡外邪,脾胃运化水湿无力致痰湿内生、胃中郁热,进一步为HP定植在胃黏膜上提供前提条件 [23] ,也使得人体更容易受外邪侵袭。

3.2. 抑郁症的中医病因病机

中医古籍虽然没有抑郁症病名,多数学者认为抑郁症当属中医“郁证”的范畴,但在“脏躁”、“百合病”、“癫证”、“不寐”等篇章中可见抑郁症状,内容丰富 [24] 。与抑郁症关系最密切的是“郁证”当中的情志之郁,情志之郁的病机包括虚和实两个方面,实症的病机是情志不调引起“五郁”及“六郁”;虚证的病机则多因情志过极伤及五脏,脏腑功能失调。抑郁症的胃肠道症状与中医情志抑郁所致的“肝胃不和证”临床表现上具有一致性。

3.3. 两者共病的病机分析

基于肝胃不和的中医理论,我们发现HP感染后的胃气失和致使肝气郁结型抑郁症是有一定理论依据的。HP为湿热之邪,自体外侵袭人体,根植于胃,致使胃内湿热丛生、胃气失和,一方面影响脾胃运化,另一方面影响气机升降,影响于肝。胃气失和,湿热内阻则脾胃运化无力,进一步加重湿邪困顿,湿邪阻遏气机,也削弱了脾胃运化水谷之力,则气血生化无源。或机体平素嗜食肥甘或饮食不节等,胃气本虚,胃内湿热丛生,HP为湿热之邪,两者湿热之类,同气相求,则此类人群更易感HP。胃气失和后,胃气当降不降,则见恶心欲吐、呃逆、反酸等症,湿邪困顿则见食欲不振、小便不利、便溏等症。气血生化无源则肝血难以濡养,无力制于肝气,致使肝疏泄太过或不及,疏泄太过则肝气横逆,再犯于胃,可见胁痛、胃痛、烦躁易怒等证,若疏泄不及,则气机郁滞,故见太息、不寐等证。若患者平素情志抑郁,肝气郁结于胸,气机不畅,胆汁不充,脾胃不得肝气之泄、胆汁之充,则受纳腐熟无力,饮食内结未得及时运化,则湿热丛生、阻遏气机,加重肝气郁结,故郁证患者常见不思饮食、不寐等,故曰“胃不和则卧不安”。

4. 总结与展望

基于中医肝胃不和的理论,我们发现HP感染后可能会加剧肝气郁结型抑郁症的症状或成为该病的发病因素,感染HP后出现了脾胃症状后,使得患者更容易罹患抑郁症,且HP感染迁延不愈,一方面是感染HP后一定程度上给患者带来了心理负担,另一方面,感染HP使得胃气失和,胃土反侮于肝木,影响肝之疏泄,则易出现情志抑郁。HP感染诱发抑郁症的科学假说,目前缺乏大量的实验证据,可以成为今后的一个研究方向,同时也为临床上治疗两者共病提供新的思路。

NOTES

*通讯作者。

参考文献

[1] Sebastian Domingo, J.J. (2022) Irritable Bowel Syndrome. Medicina Clínica (English Edition), 158, 76-81.
https://doi.org/10.1016/j.medcle.2021.04.015
[2] Lacy, B.E. and Patel, N.K. (2017) Rome Criteria and a Diagnos-tic Approach to Irritable Bowel Syndrome. Journal of Clinical Medicine, 6, 99-106.
https://doi.org/10.3390/jcm6110099
[3] 韩亚飞, 王允亮, 李军祥. 腹泻型肠易激综合征发病机制及中药干预研究进展[J]. 辽宁中医药大学学报, 2018, 20(1): 114-117.
[4] 汪龙德, 张萍, 任培培, 等. 腹泻型肠易激综合征相关发病机制及治疗的研究进展[J]. 实用中医内科杂志, 2022, 36(1): 16-19.
[5] 王彬, 赵威, 许梦雀, 等. 肠易激综合征患者睡眠质量和精神心理状况的调查[J]. 胃肠病学, 2018, 23(3): 161-165.
[6] Oka, P., Parr, H., Bar-berio, B., et al. (2020) Global Prevalence of Irritable Bowel Syndrome According to Rome III or IV Criteria: A System-atic Review and Meta-Analysis. The Lancet Gastroenterology & Hepatology, 5, 908-917.
https://doi.org/10.1016/S2468-1253(20)30217-X
[7] Mearin, F., Lacy, B.E., Chang, L., et al. (2016) Bowel Dis-orders. Gastroenterology.
[8] 张声生, 魏玮, 杨俭勤. 肠易激综合征中医诊疗专家共识意见(2017) [J]. 中医杂志, 2017, 58(18): 1614-1620.
[9] 张艳霞, 赵蓉, 吕双然, 等. 腹泻型肠易激综合征中医证候分布与VIP, SP, 5-HT动态变化的相关性分析[J]. 河北中医药学报, 2022, 37(1): 17-20.
[10] 左军, 张金龙, 胡晓阳. 白术化学成分及现代药理作用研究进展[J]. 辽宁中医药大学学报, 2021, 23(10): 6-9.
[11] 邓桃妹, 彭代银, 俞年军, 等. 茯苓化学成分和药理作用研究进展及质量标志物的预测分析[J]. 中草药, 2020, 51(10): 2703-2717.
[12] 张燕丽, 孟凡佳, 田园, 等. 炙甘草的化学成分与药理作用研究进展[J]. 化学工程师, 2019, 33(8): 60-63+66.
[13] 邵礼梅, 许世伟. 山药化学成分及现代药理研究进展[J]. 中医药学报, 2017, 45(2): 125-127.
[14] Mmcs, J., et al. (2023) Al-pha-Ketoglutaric Acid Based Polymeric Particles for Cutaneous Wound Healing. Journal of Biomedical Materials Re-search Part A, 111, 1372-1378.
[15] He, L., Huang, N., Li, H., et al. (2017) AMPK/α-Ketoglutarate Axis Regulates In-testinal Water and Ion Homeostasis in Young Pigs. Journal of Agricultural and Food Chemistry, 65, 2287-2298.
https://doi.org/10.1021/acs.jafc.7b00324
[16] Camilleri, M. (2019) Implications of Pharmacogenomics to the Man-agement of IBS. Clinical Gastroenterology and Hepatology, 17, 584-594.
https://doi.org/10.1016/j.cgh.2018.04.052
[17] Puszkiel, A., Arellano, C., Vachoux, C., et al. (2021) Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer. Clinical Pharmacology & Therapeutics, 109, 1244-1255.
https://doi.org/10.1002/cpt.2077
[18] Liu, J., Lu, Y.F., Corton, J.C., et al. (2021) Expression of Cytochrome P450 Isozyme Transcripts and Activities in Human Livers. Xenobiotica, 51, 279-286.
https://doi.org/10.1080/00498254.2020.1867929
[19] Yi, Y.L., Li, Y., Guo, S., et al. (2022) Elucidation of the Reinforcing Spleen Effect of Jujube Fruits Based on Metabolomics and Intestinal Flora Analysis. Frontiers in Cellular and Infection Microbiology, 12, Article ID: 847828.
https://doi.org/10.3389/fcimb.2022.847828
[20] Effendi, W.I. and Nagano, T. (2023) A2B Adenosine Receptor in Idiopathic Pulmonary Fibrosis: Pursuing Proper Pit Stop to Interfere with Disease Progression. International Journal of Molecular Sciences, 24, Article No. 4428.
https://doi.org/10.3390/ijms24054428
[21] 刘汝霏, 吴萌, 尚杰. 单磷酸腺苷活化蛋白激酶通过调控能量代谢对肿瘤发挥双重作用的研究进展[J]. 中华肿瘤防治杂志, 2023, 30(17): 1069-1078.
[22] De Lera Ruiz, M., Lim, Y.H. and Zheng, J. (2014) Adenosine A2A Receptor as a Drug Discovery Target. Journal of Medicinal Chemistry, 57, 3623-3650.
https://doi.org/10.1021/jm4011669
[23] Effendi, W.I., Nagano, T., Kobayashi, K., et al. (2020) Focus-ing on Adenosine Receptors as a Potential Targeted Therapy in Human Diseases. Cells, 9, Article No. 785.
https://doi.org/10.3390/cells9030785
[24] Ishioh, M., et al. (2021) Activation of Central Adenosine A2B Receptors Mediate Brain Ghrelin-Induced Improvement of Intestinal Barrier Function through the Vagus Nerve in Rats. Experi-mental Neurology, 341, Article ID: 113708.
https://doi.org/10.1016/j.expneurol.2021.113708